Please provide your email address to receive an email when new articles are posted on . Statin therapy was tied to a 5-year CVD risk reduction in adults aged 75 years and older. Statin use did not ...

The number of patients taking statins for primary prevention has increased in the United States over the past two decades, but the percentage of eligible patients on treatment has appeared to plateau ...

Please provide your email address to receive an email when new articles are posted on . Black and Hispanic adults are less likely to use statins compared with white adults. Having health insurance or ...

In adults aged 80 years or older, the use of statins is linked to a lower risk for all-cause mortality and new coronary events.

Patients 80 years of age and older experienced a 31% reduction in mortality and a 20% reduction in the risk of new coronary events when they participated in statin therapy, according to a March study ...

ATLANTA, GA—More than 90% of patients get it right when it comes to appropriately selecting themselves as candidates for over-the-counter statin therapy, according to results from the TACTiC study.

Future Cardiol. 2009;5(1):1-4. That leaves extrapolation from secondary prevention women's results to support primary prevention statin use, yet the risk profiles for women in the two groups obviously ...

Researchers analyzed large real-world datasets to evaluate statin therapy across underrepresented patient groups. Their studies confirmed that statins lower cardiovascular risk without increasing ...

In this study, authors assessed the proportion of patients with nonalcoholic fatty liver disease (NAFLD) receiving prescriptions for statins in primary care. Objectives: Cardiovascular disease is the ...

People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of preventive management than in the general population. Last year, an HHS panel ...

SAN DIEGO -- Bempedoic acid (Nexletol) prevented cardiovascular events in high-risk, statin-intolerant patients who had not yet had an event, a subgroup analysis from the CLEAR Outcomes trial ...